Literature DB >> 27465327

Impact of operative and peri-operative factors on the long-term prognosis of primary liver cancer patients undergoing hepatectomy.

Li-Ning Xu1, Ying-Ying Xu2, De-Wei Gao3.   

Abstract

This study examined the impact of the operative and peri-operative factors on the long-term prognosis of patients with primary liver cancer undergoing hepatectomy. A total of 222 patients with primary liver cancer who underwent hepatectomy were followed up from January 1986 to December 2010 at Chinese PLA General Hospital. The post-operative complication rate was 14.0% for all cases, 13.7% for hepatocellular carcinoma (HCC), 10.0% for cholangiocarcinoma. The 1-, 3-, 5- and 10-year overall survival rates in patients with primary liver cancer after resection were 76.6%, 57.6%, 41.4%, and 21.0%. The survival rates were significantly higher in the HCC group than in the cholangiocarcinoma group (P=0.000), in the non-anatomical resection group than in the anatomical resection group (P=0.005), in the female group than in the male group (P=0.002), in patients receiving no blood transfusion than in those who were given intra-operative blood transfusion (P=0.000), in patients whose intra-operative blood loss was less than 400 mL than in those who intra-operatively lost more than 400 mL (P=0.000). No significant difference was found in the survival rate between the HBsAg-positive group and the HBsAg-negative group (P=0.532). Our study showed that anatomical resection, blood loss and blood transfusion were predictors of poor survival after hepatectomy for primary liver cancer patients, and concomitant hepatitis B virus infection bore no relation with the post-resection survival.

Entities:  

Keywords:  hepatectomy; influencing factors; perioperative time; primary liver cancer; prognosis

Mesh:

Substances:

Year:  2016        PMID: 27465327     DOI: 10.1007/s11596-016-1619-2

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  22 in total

Review 1.  Survival after anatomic resection versus nonanatomic resection for hepatocellular carcinoma: a meta-analysis.

Authors:  Jinggui Chen; Kai Huang; Jianghong Wu; Huiyan Zhu; Yingqiang Shi; Yanong Wang; Guangfa Zhao
Journal:  Dig Dis Sci       Date:  2010-11-17       Impact factor: 3.199

2.  A comprehensive meta-regression analysis on outcome of anatomic resection versus nonanatomic resection for hepatocellular carcinoma.

Authors:  Alessandro Cucchetti; Matteo Cescon; Giorgio Ercolani; Eleonora Bigonzi; Guido Torzilli; Antonio D Pinna
Journal:  Ann Surg Oncol       Date:  2012-06-22       Impact factor: 5.344

3.  Liver regeneration stimulates tumor metastases.

Authors:  Nadia Harun; Mehrdad Nikfarjam; Vijayaragavan Muralidharan; Christopher Christophi
Journal:  J Surg Res       Date:  2007-01-24       Impact factor: 2.192

4.  Diagnosis and surgical treatment of primary hepatic cholangiocarcinoma.

Authors:  Shao-liang Han; Guan-bao Zhu; Jian-gao Yao; Sheng-hong Lan; Yong-Fu Shao
Journal:  Hepatogastroenterology       Date:  2005 Mar-Apr

5.  Important prognostic factors for the long-term survival of subjects with primary liver cancer in Taiwan: a hyperendemic area.

Authors:  Ping-Ho Chen; Ying-Chu Lin; Hung-Pin Tu; Shang-Lun Chiang; Albert Min-Shan Ko; Chun-Lan Hsu; Yu-Fang Chang; Ying-Chin Ko
Journal:  Eur J Cancer       Date:  2007-02-27       Impact factor: 9.162

6.  Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma.

Authors:  K Hanazaki; S Kajikawa; N Shimozawa; M Mihara; K Shimada; M Hiraguri; N Koide; W Adachi; J Amano
Journal:  J Am Coll Surg       Date:  2000-10       Impact factor: 6.113

Review 7.  Epidemiology of liver cancer: an overview.

Authors:  Petcharin Srivatanakul; Hutcha Sriplung; Somyos Deerasamee
Journal:  Asian Pac J Cancer Prev       Date:  2004 Apr-Jun

8.  Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases.

Authors:  Yoshiko Yano; Junji Yamamoto; Tomoo Kosuge; Yoshihiro Sakamoto; Susumu Yamasaki; Kazuaki Shimada; Hidenori Ojima; Michiie Sakamoto; Tadatoshi Takayama; Masatoshi Makuuchi
Journal:  Jpn J Clin Oncol       Date:  2003-06       Impact factor: 3.019

9.  Comparison between disease free survival of hepatocellular carcinoma after hepatic resection in chronic hepatitis B patients with or without cirrhosis.

Authors:  Karjpong Techathuvanan; Sithipong Srisajjakul; Ananya Pongpaibul; Somchai Limsrichamrern; Phunchai Charatcharoenwitthaya; Siwapom Chainuvati; Tawesak Tanwandee; Watcharasak Chotiyaputta
Journal:  J Med Assoc Thai       Date:  2015-04

10.  Liver resection for intrahepatic cholangiocarcinoma.

Authors:  Felice Giuliante; Riccardo Gauzolino; Maria Vellone; Francesco Ardito; Marino Murazio; Gennaro Nuzzo
Journal:  Tumori       Date:  2005 Nov-Dec
View more
  4 in total

1.  Pancreatic neuroendocrine neoplasms: Correlation between MR features and pathological tumor grades.

Authors:  Feng Jin; Kai Wang; Ting-Ting Qin; Xin Li; Feng Guo; Gui-Na Ma; Xue-Han Hu; Ping Han
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-08-08

Review 2.  The impact of perioperative allogeneic blood transfusion on prognosis of hepatocellular carcinoma after radical hepatectomy: A systematic review and meta-analysis of cohort studies.

Authors:  Yangqin Xun; Hongwei Tian; Lidong Hu; Peijing Yan; Kehu Yang; Tiankang Guo
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

3.  Individualized risk estimation for postoperative pulmonary complications after hepatectomy based on perioperative variables.

Authors:  Li-Ning Xu; Ying-Ying Xu; Gui-Ping Li; Bo Yang
Journal:  World J Gastrointest Surg       Date:  2022-07-27

4.  Impact of intramuscular adipose tissue content on short- and long-term outcomes of hepatectomy for colorectal liver metastasis: a retrospective analysis.

Authors:  Nobutoshi Horii; Yu Sawda; Takafumi Kumamoto; Nobuhiro Tsuchiya; Takashi Murakami; Yasuhiro Yabushita; Yuki Honma; Ryusei Matsuyama; Daisuke Morioka; Hirotoshi Akiyama; Itaru Endo
Journal:  World J Surg Oncol       Date:  2020-04-07       Impact factor: 2.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.